ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MAZE vs ALVO // RETURN ON INVESTED CAPITAL (ROIC)

Maze Therapeutics Inc. (NASDAQ) VS. Alvotech (NASDAQ) • 15-METRIC TALLY: MAZE 1 — ALVO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAZE VS. ALVO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MAZE ALVO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.36% — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 63.3 38.9 +24.38 MAZE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.77B $1.91B -$135.5M ALVO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MAZE REV ALVO REV MAZE GROSS % ALVO GROSS % MAZE FCF ALVO FCF
FY 2025 $0 — — — -$112.7M —
FY 2024 $167.5M — — — $74.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAZE // BETA —
ALVO // BETA —